Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]

다국어 초록 (Multilingual Abstract)

Selective “targeted” delivery of chemotherapeutic agents represents a molecular strategy for achieving enhanced margins-ofsafety and greater potency compared to conventional small-molecular weight chemotherapeutics. Greater margins-of-safety are possible because extensive un-intentional diffusion of therapeutics across intact cell membranes of normal healthy cells residing within tissues and organ systems is minimized or avoided. Simultaneous, independent “targeted” delivery of one or more therapeutics at multiple sites on the external surface membrane of neoplastic cells has not been described extensively.
Fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] and dexamethasone-(C21-phosphoramidate)-[anti-EGFR] were synthesized by reacting fludarabine or dexamethasone-C21-monophosphate with a carbodiimide reagent and imidazole for synthesis of covalent fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] and dexamethasone-(C21-phosphoramidate)-[anti- EGFR] immunopharmaceuticals. The pharmaceutical molar-incorporation-indexes for fludarabine-(C5-phosphoramidate)- [anti-IGF-1R] and dexamethasone-(C21-phosphoramidate)-[anti-EGFR] were 3.67:1 and 6.95:1 respectively. Simultaneous dual-combination selective “targeted” delivery with fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] with dexamethasone-( C21-phosphoramidate)-[anti-EGFR] produced the most profound enhancement in anti-neoplastic cytotoxitity at the pharmaceutical-equivalent concentations of 10− 9 M (14.7% ± 0.80 SE) and 10− 8 M (54.0% ± 0.9 SE) respectively.
Simultaneous dual “targeted” anti-neoplastic cytotoxicity can potentially be evoked ex-vivo and in-vivo with fludarabine- (5′-phosphoramidate)-[anti-IGF-1R] and dexamethasone-(C21-phosphoramidate)-[anti-EGFR] through the synergistic and additive efficacy achieved through the combined mechanisms-of-actions associated with; (1) covalently bound therapeutic moieties; (2) anti-trophic receptor IgG-immunoglobulin; and (3) activation of three host immune responses.

참고문헌 (Reference)

• 1 Meden H, "Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study" 21 (21): 1301-1305, 2001
• 2 Slamon DJ, "Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2" 344 (344): 786-792, 2001
• 3 Sirova M, "Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces longlasting systemic anti-tumor immunity in mice" 56 : 35-47, 2007
• 4 Narayan M, "Trastuzumab-induced HER reprogramming in"resistant"breast carcinoma cells" 69 (69): 2191-2194, 2009
• 5 Barok M, "Trastuzumab-DM1causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in-vivo" 13 (13): R46-, 2011
• 6 Pegram MD, "Trastuzumab and chemotherapeutics: drug interactions and synergies" 27 (27): 21-25, 2000
• 7 Lam W, "Toxicity and DNA binding of dextran-doxorubicin conjugates in multidrug-resistant KB-V1 cells : optimization of dextran size" 11 : 377-384, 2000
• 8 Golf SW, "Thin-layer chromatography—the forgotten alternative for the quantitative determination of steroids" 2 : 189-192, 1987
• 9 Paw B, "Thin-layer chromatographic analysis of fludarabine and formycin A in human plasma" 57 : 341-343, 2000
• 10 Sivam GP, "Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma" 55 (55): 2352-2356, 1995
• 11 Marjanovic G, "The use of inexpensive broad spectrum lower toxicity therapeutics in chronic lymphocytic leukemia" 22 : 288-294, 2017
• 12 Harris CA, "The efficacy of HER2-targeted agents in metastatic breast cancer : a meta-analysis" 22 (22): 1308-1317, 2011
• 13 Honeywell R, "The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry" 847 : 142-152, 2007
• 14 Nanda R, "Targeting the human epidermal growth factor receptor 2(HER2)in the treatment of breast cancer : recent advances and future directions" 2 (2): 111-116, 2007
• 15 Granfeldt A, "Targeting dexamethasone to macrophages in a porcine endotoxemic model" 41 : e309-e318, 2013
• 16 Lewis Phillips GD, "Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate" 68 (68): 9280-9290, 2008
• 17 Coyne CP, "Synthesis of gemcitabine-(C4-amide)-[anti-HER2/neu] utilizing a UV-photoactivated gemcitabine intermediate : cytotoxic anti-Neoplastic activity against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3" 3 : 689-711, 2012
• 18 Coyne CP, "Synthesis of epirubicin-(C3-amide)-[anti-HER2/neu] utilizing a UV-photoactivated epirubicin" 27 : 41-55, 2012
• 19 Liang JF, "Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity" 15 : 5071-5075, 2005
• 20 Coyne CP, "Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma" 19 : 67-76, 2011
• 21 Kruger M, "Synthesis and stability of four maleimide derivatives of the anticancer drug doxorubicin for the preparation of chemoimmunoconjugates" 45 (45): 399-401, 1997
• 22 Surabhi P, "Synthesis and evaluation of phosphoramide mustard prodrugs for site-specific activation" Rutgers University 2007
• 23 Stacchiotti S, "Sunitinib malate and figitumumab in solitary fibrous tumor : patterns and molecular bases of tumor response" 9 : 1286-1297, 2010
• 24 Furgeson DY, "Structural optimization of a"smart"doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors" 110 : 362-369, 2006
• 25 De Goeij AF, "Steroidbovine serum albumin conjugates : molecular characterization and their interaction with androgen and estrogen receptors" 24 : 1017-1031, 1986
• 26 Singh R, "Stability-Indicating HPLC Determination of Gemcitabine in Pharmaceutical Formulations" 1-12, 2015
• 27 Diener E, "Specific immunosuppression by immunotoxins containing daunomycin" 231 (231): 148-150, 1986
• 28 Belz K, "Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly" 124 : 240-250, 2014
• 29 Coyne CP, "Simultaneous dual selective targeted delivery of two covalent gemcitabine immunochemotherapeutics and complementary anti-neoplastic potency of [Se]-methylselenocysteine" 6 : 62-89, 2015
• 30 Lammers T, "Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers" 30 (30): 3466-3475, 2009
• 31 Dillman RO, "Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates" 1 : 250-255, 1989
• 32 Everts M, "Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate" 168 : 883-889, 2002
• 33 Habermann TM, "Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma" 24 : 3121-3127, 2006
• 34 Santos-Lozano A, "Response rate to the treatment of Waldenström macroglobulinemia : a meta-analysis of the results of clinical trials" 105 : 118-126, 2016
• 35 Pietras RJ, "Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNAreactive drugs" 17 (17): 2235-2249, 1998
• 36 Slamon D, "Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials" 28 (28): 13-19, 2001
• 37 Dempke W, "Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma" 30 (30): 4673-4677, 2010
• 38 Wang LZ, "Rapid determination of gemcitabine and its metabolite in human plasma by LC–MSMS through micro protein precipitation with minimum matrix effect" 1 : 23-32, 2009
• 39 Kratz F, "Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound" 45 : 5523-5533, 2002
• 40 Li ZH, "Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin" 2013
• 41 Fleury I, "Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia" 4 : 331-341, 2004
• 42 Wang P, "Phosphate-specific fluorescence labeling with BO-IMI : reaction details" 809 : 211-218, 1998
• 43 Wang P, "Phosphate-specific fluorescence labeling of pepsin by BO-IMI" 230 : 329-332, 1995
• 44 Lin NU, "Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer" 26 (26): 1993-1999, 2008
• 45 Unger C, "Phase I and pharmacokinetic study of the(6-maleimidocaproyl)hydrazone derivative of doxorubicin" 13 (13): 4858-4866, 2007
• 46 Oliveras-Ferraros C, "Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype : new insights into de novo resistance to trastuzumab(Herceptin)" 37 (37): 669-678, 2010
• 47 Wong BK, "PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolite" 29 : 313-318, 2001
• 48 Bürkle A, "Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia" 110 : 3316-3325, 2007
• 49 Dubikovskaya EA, "Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters" 105 : 12128-12133, 2008
• 50 Hu Q, "One-step conjugation of aminoferrocene to phosphate groups as electroactive probes for electrochemical detection of sequence-specific DNA" 65 : 71-77, 2015
• 51 Lau A, "Novel doxorubicinmonoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in-vivo" 3 : 1305-1312, 1995
• 52 Sliwkowski M, "Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)" 26 (26): 60-70, 1999
• 53 Kaneko T, "New hydrazone derivatives of adriamycin and their immunoconjugates : A correlation between acid-stability and cytotoxicity" 2 : 133-141, 1991
• 54 Winer EP, "New combinations with Herceptin in metastatic breast cancer" 61 (61): 50-57, 2001
• 55 Waber DP, "Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia : findings from Dana-Farber Cancer Institute All Consortium Protocol 00–01" 60 : 1785-1791, 2013
• 56 Gopal AK, "Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age = 60 years with B cell lymphoma" 20 : 770-775, 2014
• 57 Köninki K, "Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells" 294 (294): 211-219, 2010
• 58 Cobleigh MA, "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease" 17 (17): 2639-2648, 1999
• 59 Sinkule JA, "Monoclonal antibody 44-3A6 doxorubicin immunoconjugates : comparative in-vitro anti-tumor efficacy of different conjugation methods" 12 (12): 198-206, 1991
• 60 Huang YF, "Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells" 10 : 862-868, 2009
• 61 Kanat O, "Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma" 19 : 344-347, 2010
• 62 Mao Y, "Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74 +B-cell malignancies" 19 : 347-356, 2013
• 63 He XK, "Low molecular weight hydroxyethyl chitosan-prednisolone conjugate for renal targeting therapy : synthesis, characterization and in vivo studies" 2 : 1054-1063, 2012
• 64 Watson E, "Kinetics of phosphoramide mustard hydrolysis in aqueous solutions" 74 : 1283-1292, 1985
• 65 Reményi J, "Isomer-dependent daunomycin release and in vitro antitumour effect of cis-aconityl-daunomycin" 4 (4): 556-561, 2003
• 66 Boone JJ, "Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents" 8 (8): 3015-3023, 2009
• 67 Oliveras-Ferraros C, "Inhibitor of Apoptosis(IAP)survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies" 407 (407): 412-419, 2011
• 68 Ren Y, "Inhibition of P-glycoprotein and increasing of drug-sensitivity of a human carcinoma cell line(KB-A-1)by an anti-sense oligodeoxynucleotide-doxorubicin conjugate in vitro" 41 : 137-143, 2005
• 69 Inapagolla R, "In-vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation" 399 : 140-147, 2010
• 70 Ren Y, "In-vitro reversal MDR of human carcinoma cell line by an antisense oligodeoxynucleotide-doxorubicin conjugate" 58 (58): 520-526, 2004
• 71 Ajaj KA, "In-vitro and invivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B" 64 : 413-418, 2009
• 72 Ryppa C, "In-vitro and in-vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin aVb3" 19 : 1414-1422, 2008
• 73 Stephens DM, "Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy" 27 : 303-327, 2013
• 74 Bouvet E, "Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia" 98 : 65-70, 2013
• 75 Ogden JR, "Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of cisaconityl-doxorubicin : preparation and in vitro cytotoxicity" 1 (1): 170-174, 1989
• 76 Ritter CA, "Human breast cancer cells selected for resistance to trastuzumab in-vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network" 13 (13): 4909-4919, 2007
• 77 Beloglazova NG, "Highly efficient site-directed RNA cleavage by imidazole-containing conjugates of antisense oligonucleotides" 36 : 731-739, 2002
• 78 Kirstein MN, "High-performance liquid chromatographic method for the determination of gemcitabine and 2′, 2′-difluorodeoxyuridine in plasma and tissue culture media" 835 : 136-142, 2006
• 79 Nastoupil LJ, "High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone(R-FND)with interferon maintenance in indolent lymphoma : Results of a Randomized Study" 177 : 263-270, 2017
• 80 Krakovicova H, "HPMA-based polymerconjugates with drug combinations" 37 (37): 4050-4412, 2009
• 81 Ulbrich K, "HPMA copolymers with pH-controlled release of doxorubicin : In-vitro cytotoxicity and in-vivo antitumor activity" 87 : 33-47, 2003
• 82 Mazuel C, "HPLC-MS/MS determination of a peptide conjugate prodrug of doxorubicin, and its active metabolites, leucine-doxorubicin and doxorubicin, in dog and rat plasma" 33 (33): 1093-1102, 2003
• 83 Wielckens K, "Glucocorticoid-induced lymphoma cell death : the good and the evil" 27 : 413-419, 1987
• 84 Coyne CP, "Gemcitabine-(5′-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)" 2016
• 85 Limmer S, "Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes" 31 : 2276-2286, 2014
• 86 Lynn KD, "GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer" 10 : 397-, 2010
• 87 Zinzani PL, "Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin’s lymphoma:experience on 142 patients" 88 : E273-E276, 2013
• 88 Coyne CP, "Fludarabine-(C 2-methylhydroxyphosphoramide)-[anti-IGF-1R] : synthesis and selectively"targeted"anti-neoplastic cytotoxicity against pulmonary adenocarcinoma(A549)" 4 : 129-, 2015
• 89 Šimkoviè M, "Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia" 12 : 421-427, 2016
• 90 Lim SH, "Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy" 118 : 2530-2540, 2011
• 91 Watanabe N, "Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab" 10 : 357-361, 2005
• 92 El-Mabhouh AA, "Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells" 123 : 3780-3789, 2014
• 93 Greenfield RS, "Evaluation in-vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker" 50 (50): 6600-6607, 1990
• 94 Landriscina M, "Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells" 30 (30): 473-480, 2010
• 95 Coyne CP, "Epirubicin-[anti-HER2/neu] synthesized with an epirubicin-(C13-imino)-EMCS analog : Anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma in combination with organic selenium" 2 (2): 22-39, 2011
• 96 Marches R, "Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab(Herceptin)on HER2-overexpressing tumor cells" 112 (112): 492-501, 2004
• 97 Fernández-Calotti PX, "Enhancement of fludarabine sensitivity by all-transretinoic acid in chronic lymphocytic leukemia cells" 97 : 943-945, 2012
• 98 Vogel CL, "Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer" 20 (20): 719-726, 2002
• 99 Gupta P, "Dual-targeting immunotherapy of lymphoma : potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas" 119 : 3767-3778, 2012
• 100 Coyne CP, "Dual potency anti-HER2/neu and anti-EGFR anthracycline-immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin-A and verapamil P-glycoprotein inhibition" 17 : 474-489, 2009
• 101 Asakura T, "Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells" 8 : 199-203, 1997
• 102 Wang F, "Doxorubicingallium-transferrin conjugate overcomes multidrug resistance:evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells" 20 (20): 799-808, 2000
• 103 Mazel M, "Doxorubicin-peptide conjugates overcome multidrug resistance" 12 : 107-116, 2001
• 104 Inoh K, "Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug" 36 (36): 207-211, 2006
• 105 Yang HM, "Doxorubicin conjugated with monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses growth of established tumor xenografts in nude mice" 85 : 1189-1193, 1988
• 106 Cao N, "Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate(TPGS) : conjugation chemistry, characterization, in-vitro and in-vivo evaluation" 29 (29): 3856-3865, 2008
• 107 Kovar L, "Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells" 31 (31): 233-242, 2010
• 108 Warris LT, "Does dexamethasone induce more neuropsychological side effects than prednisone in pediatric acute lymphoblastic leukemia? A systematic review" 61 : 1313-1318, 2014
• 109 Klabusay M, "Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34 +cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases" 72 : 363-370, 2007
• 110 Beyer U, "Difference in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal-formulated doxorubicin as shown by confocal microscopy" 18 : 29-38, 2001
• 111 Lerza R, "Dexamethazone-induced acute tumor lysis syndrome in a T-cell malignant lymphoma" 43 : 1129-1132, 2002
• 112 Coyne CP, "Dexamethasone-(C21-phosphoramide)-[anti-EGFR] : molecular design, synthetic organic chemistry reactions and anti-neoplastic cytotoxic potency against pulmonary adenocarcinoma(A549)" 10 : 2575-2597, 2016
• 113 Domenech C, "Dexamethasone(6 mg/m2/day)and prednisolone(60 mg/m2/day)were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial" 99 : 1220-1227, 2014
• 114 Edelmann MN, "Dexamethasone exposure and memory function in adult survivors of childhood acute lymphoblastic leukemia : a report from the SJLIFE cohort" 60 : 1778-1784, 2013
• 115 Melgert BN, "Dexamethasone coupled to albumin is selectively taken up by rat nonparenchymal liver cells and attenuates LPSinduced activation of hepatic cells" 32 : 603-611, 2000
• 116 Funk D, "Development of a novel polyethylene glycol-corticosteroid-conjugate with an acid-cleavable linker" 19 : 434-445, 2011
• 117 Trail PA, "Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates" 261 : 212-215, 1993
• 118 Griffiths GL, "Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate" 9 (9): 6567-6571, 2003
• 119 Page M, "Coupling a preactivated daunorubicin derivative to antibody. A new approach" 10 : 353-357, 1990
• 120 Onishi H, "Conjugate between chondroitin sulfate and prednisolone with a glycine linker : preparation and in vitro conversion analysis" 61 : 902-912, 2013
• 121 Zhang L, "Combined anti-fetal liver kinase 1 monoclonal antibody(anti-VEGFR)and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis" 62 (62): 2034-2042, 2002
• 122 Quek R, "Combination mTOR and IGF-1R inhibition : phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors" 17 : 871-879, 2011
• 123 Huang SJ, "Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada" 55 : 79-90, 2017
• 124 Kim S, "Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice" 12 (12): 600-607, 2006
• 125 Awan FT, "CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody" 115 : 1204-1213, 2010
• 126 Kute TE, "Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing" 58 (58): 1887-1896, 2009
• 127 Pimm M, "Biodistribution and tumour localization of a daunomycin-monoclonal antibody conjugate in nude mice and human tumour xenografts" 27 (27): 267-271, 1988
• 128 Ratcliffe KE, "Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action" 147 : 571-579, 2006
• 129 García-Sáenz JA, "Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline-and taxanerefractory breast cancer" 20 (20): 632-639, 2008
• 130 Perello L, "Application of high-performance, thin-layer chromatography to quality control of antimetabolite analogue infusion bags" 84 : 1296-1300, 2001
• 131 Régina A, "Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2" 155 : 185-197, 2008
• 132 Ciardiello F, "Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225" 5 (5): 909-916, 1999
• 133 Stan AC, "Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen" 59 : 115-121, 1999
• 134 Coyne CP, "Anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-EGFR] in dual-combination with epirubicin-(C3-amide)-[anti-HER/neu] against chemotherapeutic-resistant mammary adenocarcinoma(SKBr-3)and the complementary effect of mebendazole" 2 : 1-22, 2014
• 135 Sapra P, "Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograph and in monkeys" 11 (11): 5257-5264, 2005
• 136 Alfonso-Pérez M, "Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia" 79 : 1157-1165, 2006
• 137 Weaver DJ, "Analysis of rates of receptor-mediated endocytosis and exocytosis of a fluorescent hapten-protein conjugate in murine macrophage : implications for antigen processing" 90 : 169-181, 1998
• 138 Mitra D, "An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance" 8 (8): 2152-2162, 2009
• 139 Chen FL, "Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors" 14 (14): 6730-6734, 2008
• 140 Rodrigues PC, "Acid-sensitive polyethylene glycol conjugates of doxorubicin : preparation, in vitro efficacy and intracellular distribution" 7 (7): 2517-2524, 1999
• 141 Patel H, "A validated stability-indicating HPTLC method for the estimation of gemcitabine HCl in its dosage form" 25 : 77-80, 2012
• 142 Bidwell GL(III), "A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance" 25 : 313-326, 2007
• 143 Söderberg A, "A protein disulfide isomerase/thioredoxin-1 complex is physically attached to exofacial membrane tumor necrosis factor receptors : overexpression in chronic lymphocytic leukemia cells" 18 : 363-375, 2013
• 144 Rao KS, "A novel route for immobilization of oligonucleotides onto modified silica nanoparticles" 576 : 177-183, 2006
• 145 Di Stefano G, "A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond : Synthesis, characterization and preliminary biological properties of the conjugate" 23 : 393-397, 2004
• 146 Basu A, "A direct antigen heterologous enzyme immunoassay for measuring progesterone in serum without using displacer" 71 : 222-230, 2006
• 147 Chiu ML, "A convenient homogeneous enzyme immunoassay for estradiol detection" 58 : 75-82, 2011